These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

837 related items for PubMed ID: 32702598

  • 1. Differential risks of immune-related colitis among various immune checkpoint inhibitor regimens.
    Yao J, Li M, Zhang H, Ge Y, Weygant N, An G.
    Int Immunopharmacol; 2020 Oct; 87():106770. PubMed ID: 32702598
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Effectivity and safety of PD-1/PD-L1 inhibitors for different level of PD-L1-positive, advanced NSCLC: A meta-analysis of 4939 patients from randomized controlled trials.
    Shi Y, Duan J, Guan Q, Xue P, Zheng Y.
    Int Immunopharmacol; 2020 Jul; 84():106452. PubMed ID: 32339922
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Combination therapy with PD-1 or PD-L1 inhibitors for cancer.
    Hayashi H, Nakagawa K.
    Int J Clin Oncol; 2020 May; 25(5):818-830. PubMed ID: 31549270
    [Abstract] [Full Text] [Related]

  • 11. Case series of cancer patients who developed cholecystitis related to immune checkpoint inhibitor treatment.
    Abu-Sbeih H, Tran CN, Ge PS, Bhutani MS, Alasadi M, Naing A, Jazaeri AA, Wang Y.
    J Immunother Cancer; 2019 May 03; 7(1):118. PubMed ID: 31053161
    [Abstract] [Full Text] [Related]

  • 12. Immune-Related Neurological Toxicities of PD-1/PD-L1 Inhibitors in Cancer Patients: A Systematic Review and Meta-Analysis.
    Tian Y, Gao A, Wen Q, Wang S, Zhang S, Yang X, Su G, Sun Y.
    Front Immunol; 2020 May 03; 11():595655. PubMed ID: 33391266
    [Abstract] [Full Text] [Related]

  • 13. Treatment-related adverse events of PD-1 and PD-L1 inhibitor-based combination therapies in clinical trials: a systematic review and meta-analysis.
    Zhou X, Yao Z, Bai H, Duan J, Wang Z, Wang X, Zhang X, Xu J, Fei K, Zhang Z, Tan F, Xue Q, Gao S, Gao Y, Wang J, He J.
    Lancet Oncol; 2021 Sep 03; 22(9):1265-1274. PubMed ID: 34391508
    [Abstract] [Full Text] [Related]

  • 14. Incidence and Risk of Colitis With Programmed Death 1 Versus Programmed Death Ligand 1 Inhibitors for the Treatment of Cancer.
    Miyashita H, Mikami T, Satoi S, Cruz C, Galsky MD.
    J Immunother; 2020 Sep 03; 43(9):291-298. PubMed ID: 32960847
    [Abstract] [Full Text] [Related]

  • 15. Cardiotoxicity of immune checkpoint inhibitors: A frequency network meta-analysis.
    Liu M, Cheng X, Ni R, Zheng B, Huang S, Yang J.
    Front Immunol; 2022 Sep 03; 13():1006860. PubMed ID: 36189211
    [Abstract] [Full Text] [Related]

  • 16. The benefits and risks of CTLA4 inhibitor plus PD1/PDL1 inhibitor in stage IIIB/IV non-small cell lung cancer: A systematic analysis and meta-analysis based on randomized controlled trials.
    Liu Q, Fang Z, Liu M, Xu R, Yi F, Wei Y, Zeng L, Zhang W.
    J Clin Pharm Ther; 2021 Dec 03; 46(6):1519-1530. PubMed ID: 34101874
    [Abstract] [Full Text] [Related]

  • 17. Differential Dermatologic Adverse Events Associated With Checkpoint Inhibitor Monotherapy and Combination Therapy: A Meta-Analysis of Randomized Control Trials.
    Ge Y, Zhang H, Weygant N, Yao J.
    Front Pharmacol; 2021 Dec 03; 12():640099. PubMed ID: 34447305
    [Abstract] [Full Text] [Related]

  • 18. Cardiovascular Toxicity With PD-1/PD-L1 Inhibitors in Cancer Patients: A Systematic Review and Meta-Analysis.
    Liu S, Gao W, Ning Y, Zou X, Zhang W, Zeng L, Liu J.
    Front Immunol; 2022 Dec 03; 13():908173. PubMed ID: 35880172
    [Abstract] [Full Text] [Related]

  • 19. Risk of Thromboembolic Events in Cancer Patients Treated with Immune Checkpoint Inhibitors: A Meta-analysis of Randomized Controlled Trials.
    Ma Z, Sun X, Zhang Y, Li H, Sun D, An Z, Zhang Y.
    Thromb Haemost; 2022 Oct 03; 122(10):1757-1766. PubMed ID: 35772727
    [Abstract] [Full Text] [Related]

  • 20. Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review.
    Khoja L, Day D, Wei-Wu Chen T, Siu LL, Hansen AR.
    Ann Oncol; 2017 Oct 01; 28(10):2377-2385. PubMed ID: 28945858
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 42.